LLY News and Press, Eli Lilly and Company From 03/18/24

2024-03-18 13:31:24 ET More on WW International I Worry That WW International, Formerly Weight Watchers, May Not Survive WW International, Inc. (WW) Q4 2023 Earnings Call Transcript WW International: A Case Of Potential Value Trap WW rebounds on CEO's assuran...

2024-03-18 12:17:28 ET More on AstraZeneca 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca FY23 Earnings Review: It's OK To Buy Dip On Q4 Bottom Line Miss AstraZeneca to expand rare disease pipel...

2024-03-18 10:15:15 ET Summary On March 14, Madrigal Pharmaceuticals, Inc. announced that the FDA has granted accelerated approval for Rezdiffra, for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This accelerated approval makes Rezdiffra ...

2024-03-18 10:00:07 ET Summary Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competi...

2024-03-18 02:00:00 ET As great of an investment as Eli Lilly (NYSE: LLY) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent opportunities out there right now, and it'd be a disservice to your portfolio to ignore them entirely. ...

2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...

2024-03-17 09:00:00 ET Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case. Three Motley Fool contributors have identified unstoppable stocks they think you can buy now without any...

2024-03-17 03:24:00 ET It's hard to overstate just how successful the expansions of new diabetes treatments into the weight management arena have been for the companies that sell them. In one striking example, the market capitalization of Novo Nordisk (NYSE: NVO) , formerly a relati...

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...

2024-03-16 09:15:00 ET When a company's big plans go awry, it's always worth reconsidering the merits of an investment. On March 8, regulators at the Food and Drug Administration (FDA) gave Eli Lilly (NYSE: LLY) an unwelcome surprise. Rather than granting approval to commercialize t...